Roth Capital analyst Jotin Marango maintained a Buy rating on KalVista Pharmaceuticals Inc (KALV) yesterday and set a price target of $25. The company’s shares opened today at $22.23.
According to TipRanks.com, Marango is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.3% and a 36.4% success rate. Marango covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Actinium Pharmaceuticals, and Syros Pharmaceuticals.
Currently, the analyst consensus on KalVista Pharmaceuticals Inc is a Moderate Buy with an average price target of $28.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.57 and a one-year low of $7.73. Currently, KalVista Pharmaceuticals Inc has an average volume of 65.79K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. It offers small molecule plasma kallikrein for the treatment of hereditary angioedema; diabetic macular edema; and other plasma kallikrein-associated diseases.
